Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

AIMS: We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Obes Metab
Main Authors: Birkeland, Kåre I., Bodegard, Johan, Banerjee, Amitava, Kim, Dae Jung, Norhammar, Anna, Eriksson, Jan W., Thuresson, Marcus, Okami, Suguru, Ha, Kyoung Hwa, Kossack, Nils, Mamza, Jil Billy, Zhang, Ruiqi, Yajima, Toshitaka, Komuro, Issei, Kadowaki, Takashi
Format: Artigo
Sprog:Inglês
Udgivet: Blackwell Publishing Ltd 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756303/
https://ncbi.nlm.nih.gov/pubmed/32893440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14189
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker